Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

This action supports the development and procurement of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines. It aims to stimulate the competitive development of market-ready innovations that are cost-efficient, safe, and benefit cancer patients living with and beyond cancer. The procurement consortia must include public procurers (possibly in cooperation with private entities) and involve end-user engagement and participative research models. Solutions should be clinically validated, piloted, or upscaled in at least five different EU or Associated Countries. The project facilitates commercialisation, provides first customer references for suppliers, and supports the adoption of best practices by policymakers, healthcare providers, professionals, cancer patients, and carers.

Check your compatibility

Agency	HORIZON (EU)
Region	EU
Country	N/A
Legal form	Government organization, Other
Start date	10 Feb 2027
End date	21 Sep 2027
Max funding	EUR 8,000,000 – EUR 10,000,000 per grant
Budget	EUR 26,000,000 for this topic
Coverage	Funding coverage and conditions as specified in the Horizon Europe Work Programme General Annexes.

Grant application conditions

Admissibility conditions	Proposal page limits and layout must follow Annex A and Annex E of the Horizon Europe Work Programme General Annexes and Part B of the Application Form in the Submission System.
Eligible countries	Applicants must be from countries described in Annex B of the Horizon Europe Work Programme General Annexes. Non-EU or non-Associated Countries may be eligible if specific provisions are in place.
Applicant type	Consortia of public procurers (with optional inclusion of private procurers) targeting the development and procurement of cancer-related healthcare innovations.
Geographic implementation	Solutions must be clinically validated, piloted or upscaled in at least five different countries across EU Member States or Associated Countries.
Evaluation and award thresholds	Excellence: 4 Impact: 4 Implementation: 4 Cumulative threshold: 12
Legal and financial requirements	Applicants and projects must comply with legal and financial set-up as described in Annex C and G of the Horizon Europe Work Programme General Annexes. The granting authority may object to a transfer of ownership or exclusive licensing of results up to four years after the end of the action.
Application template and process	Use the application form available in the Submission System; refer to standard forms and guidelines provided in the Programme Reference Documents.
Market consultation requirement	Procurers are required to organise an open-market consultation before launching procurement and promote the call for tenders widely across Europe.
End-user involvement	Effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers, patient representatives, hospitals) must be ensured in all proposals.
Procurement follow-up commitment	Procurers must declare interest to purchase at least one solution resulting from the PCP if successful, and specify whether this will occur during or after the PCP.
Documentation	https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-05

Eligible expenses

Evaluation criteria

Business exclusions

Reporting

Application process

Application requirements